A Phase 3 interventional study of Inclisiran and Matching Placebo for Inclisiran in Primary Hypercholesterolemia or Mixed Dyslipidemia, sponsored by Novartis Pharmaceuticals. Completed at 28 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-01-13.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing inclisiran in Atherosclerosis — 3 open to participants now, 7 under way, 4 of them phase 3. inclisiran · Atherosclerosis.
Among the 16 studies testing inclisiran in Atherosclerosis, this one is the 12th largest by enrollment, is one of 2 that started in 2023, is one of 8 in phase 3, and was the 9th registered.
1,519 studies on the registry are indexed under Atherosclerosis; 226 are open to participants now.
Browse Atherosclerosis studies →3 of the 16 studies testing inclisiran in Atherosclerosis are open now, in 4 countries. Recruiting first, the newest first:
University Medical Centre Ljubljana · Sites in Slovenia
Ages 18+
Novartis Pharmaceuticals · Sites in Argentina, Brazil
Ages 18–100
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 30–50
By country, each count listing its studies:
inclisiran: first FDA approval 2021 (LEQVIO), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 163 Atherosclerosis studies recruiting now, 85 (52%) set no upper age limit and 34 (21%) stop at 75 or younger; 16 take children under 18; 35 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 207 is above the median of 100 across 881 interventional studies indexed under Atherosclerosis.
Median enrollment 401 across the 16 interventional studies. Of the 8 that completed or were terminated, 6 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 16 have an industry lead sponsor. The 8 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
27 studies in Atherosclerosis by Novartis: 4 open now, 10 under way, 3 of them phase 3. Of 16 finished, 10 (63%) have results posted.
Among the 27 studies in Atherosclerosis by Novartis, this one is the 16th largest by enrollment of the 18 interventional ones that give a count, is one of 3 that started in 2023, is one of 10 in phase 3, and was the 14th registered.
Novartis’s Atherosclerosis studies by the year they started, since 2006.
4 of the studies testing inclisiran in Atherosclerosis that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05030428Phase 3Novartis PharmaceuticalsStudy of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease | 2027-05-10 |
| NCT06501443Novartis PharmaceuticalsLATAM LOWERS LDL-C | 2026-11-27 |
| NCT06249165Duke UniversityVictORION-INCLUSION: Evaluating Inclisiran for Cholesterol Managment in Heart Disease | 2026-12-31 |
| NCT07581808University Medical Centre LjubljanaDual PCSK9 Inhibition With Inclisiran and Alirocumab in Secondary Prevention | 2027-05 |
Add all 4 to your calendar (.ics) → With an account.
Among the 16 studies testing inclisiran in Atherosclerosis, from their registry updates:
Among Novartis’s 27 in Atherosclerosis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to evaluate the efficacy and safety of inclisiran as a monotherapy in Chinese adults with low or moderate atherosclerotic cardiovascular disease (ASCVD) risk and elevated low-density lipoprotein cholesterol (LDL-C) who were not on any lipid lowering therapy.
This study was designed as a randomized, double-blind, multi-center Phase III trial, with a placebo-controlled treatment period and an open label treatment period, to evaluate the efficacy and safety of inclisiran sodium 300 mg s.c. in participants aged 18 to 75 years with a low or moderate ASCVD risk and fasting LDL-C value of ≥ 130 mg/dL but \< 190 mg/dL who were not on any lipid lowering therapy.
The study consisted of 3 parts:
(inclisiran group) or matching placebo s.c. (control group) on Day 1 and Day 90. The end of core part (EOC) visit was conducted on Day 180. The database lock for the core part was planned to occur after all randomized participants have completed the EOC visit (or have discontinued from the study before EOC). The primary analysis was conducted after the database lock for the core part.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) s.c administered on Day 1, Day 90, and Day 270, and placebo on Day 180
Drug: Inclisiran · Drug: Matching Placebo for Inclisiran
Placebo on Day 1 and Day 90 and Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) s.c on Day 180 and 270
Drug: Inclisiran · Drug: Matching Placebo for Inclisiran
Inclisiran s.c
Also known as: KJX839
Matching s.c. placebo
Also known as: Placebo s.c.
Percentage Change in Low-density Lipoprotein Cholesterol (LDL-C) (mg/dL) From Baseline at Day 150 - Core Analysis: Core Part
Low-density lipoprotein cholesterol is a type of lipoprotein in the blood. Lipoproteins are particles made of lipids(fats) and proteins that carry fats through the bloodstream. Because of their structure, fats can't move through the blood on their own. So, lipoproteins carry fats to various cells in the body.
Time frame: Baseline, Day 150
Absolute Change in LDL-C (mg/dL) From Baseline at Day 150 - Core Analysis: Core Part
Low-density lipoprotein cholesterol is a type of lipoprotein in the blood. Lipoproteins are particles made of lipids(fats) and proteins that carry fats through the bloodstream. Because of their structure, fats can't move through the blood on their own. So, lipoproteins carry fats to various cells in the body.
Time frame: Baseline, Day 150
Percentage Change in Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) (ng/mL) From Baseline at Day 150 - Core Analysis: Core Part
Inclisiran is a double-stranded small interfering ribonucleic acid (siRNA) that causes degradation of protein convertase subtilisin/kexin type 9 (PCSK9) messenger RNA (mRNA) leading to the reduction of PCSK9 protein. The percentage change from baseline in PCSK9 at Day 150 was assessed.
Time frame: Baseline, Day 150
Absolute Change in PCSK9 (ng/mL) From Baseline at Day 150 - Core Analysis: Core Part
Inclisiran is a double-stranded small interfering ribonucleic acid (siRNA) that causes degradation of protein convertase subtilisin/kexin type 9 (PCSK9) messenger RNA (mRNA) leading to the reduction of PCSK9 protein.
Time frame: Baseline, Day 150
Percentage Change in Total Cholesterol (mg/dL) From Baseline at Day 150 - Core Analysis: Core Part
Total cholesterol is a measure of all the cholesterol in the blood. It includes low-density lipoprotein (LDL), high-density lipoprotein (HDL) and a portion of triglycerides.
Time frame: Baseline, Day 150
Absolute Change in Total Cholesterol (mg/dL) From Baseline at Day 150 - Core Analysis: Core Part
Total cholesterol is a measure of all the cholesterol in the blood. It includes low-density lipoprotein (LDL), high-density lipoprotein (HDL) and a portion of triglycerides.
Time frame: Baseline, Day 150
Percentage Change in High-density Lipoprotein Cholesterol (HDL-C) (mg/dL) From Baseline at Day 150 - Core Analysis: Core Part
HDL-C stands for high-density lipoprotein cholesterol, often referred to as the "good" cholesterol. This is because HDL cholesterol helps remove other forms of cholesterol from the bloodstream. It picks up excess cholesterol in the blood and carries it back to the liver, where it is broken down and flushed out of the body.
Time frame: Baseline, Day 150
Absolute Change in HDL-C (mg/dL) From Baseline at Day 150 - Core Analysis: Core Part
HDL-C stands for high-density lipoprotein cholesterol, often referred to as the "good" cholesterol. This is because HDL cholesterol helps remove other forms of cholesterol from the bloodstream. It picks up excess cholesterol in the blood and carries it back to the liver, where it is broken down and flushed out of the body.
Time frame: Baseline, Day 150
Percentage Change in Non-HDL-C (mg/dL) From Baseline at Day 150 - Core Analysis: Core Part
Non-HDL cholesterol is a measure of all the "bad" types of cholesterol in the blood, excluding HDL cholesterol. It is calculated by subtracting HDL cholesterol from total cholesterol. Non-HDL cholesterol includes all the types of cholesterol other than HDL cholesterol, and higher levels of non-HDL cholesterol can increase the risk of cardiovascular disease.
Time frame: Baseline, Day 150
Absolute Change in Non-HDL-C (mg/dL) From Baseline at Day 150 - Core Analysis: Core Part
Non-HDL cholesterol is a measure of all the "bad" types of cholesterol in the blood, excluding HDL cholesterol. It is calculated by subtracting HDL cholesterol from total cholesterol. Non-HDL cholesterol includes all the types of cholesterol other than HDL cholesterol, and higher levels of non-HDL cholesterol can increase the risk of cardiovascular disease.
Time frame: Baseline, Day 150
Percentage Change in Apolipoprotein B (ApoB) (mg/dL) From Baseline at Day 150 - Core Analysis: Core Part
Apolipoprotein B (ApoB) is a protein that helps carry fat and cholesterol through the body. It is encoded by the APOB gene. ApoB attaches to negative types of cholesterol that cause plaque buildup in blood vessels, which can lead to damage and heart disease.
Time frame: Baseline, Day 150
Absolute Change in ApoB (mg/dL) From Baseline at Day 150 - Core Analysis: Core Part
Apolipoprotein B (ApoB) is a protein that helps carry fat and cholesterol through the body. It is encoded by the APOB gene. ApoB attaches to negative types of cholesterol that cause plaque buildup in blood vessels, which can lead to damage and heart disease.
Time frame: Baseline, Day 150
Percentage Change in Apolipoprotein A-1 (ApoA-1) (mg/dL) From Baseline at Day 150 - Core Analysis: Core Part
Apolipoprotein A1 (ApoA1) is the primary protein associated with high-density lipoprotein (HDL) particles, and plays a central role in reverse cholesterol transport. HDL cholesterol (HDL-C) and ApoA1 concentrations are inversely related to the risk for coronary artery disease (CAD).
Time frame: Baseline, Day 150
Absolute Change in ApoA-1 (mg/dL) From Baseline at Day 150 - Core Analysis: Core Part
Apolipoprotein A1 (ApoA1) is the primary protein associated with high-density lipoprotein (HDL) particles, and plays a central role in reverse cholesterol transport. HDL cholesterol (HDL-C) and ApoA1 concentrations are inversely related to the risk for coronary artery disease (CAD).
Time frame: Baseline, Day 150
Percentage Change in Lipoprotein (a) (Lp(a)) (Nmol/L) From Baseline at Day 150 - Core Analysis: Core Part
Often referred to as Lp(a), lipoprotein (a) is a type of lipoprotein that is genetically inherited and in high levels is a common independent risk factor for heart disease.
Time frame: Baseline, Day 150
Absolute Change in Log-transformed Lp(a) (Nmol/L) From Baseline at Day 150 - Core Analysis: Core Part
Often referred to as Lp(a), lipoprotein (a) is a type of lipoprotein that is genetically inherited and in high levels is a common independent risk factor for heart disease.
Time frame: Baseline, Day 150
Percentage Change in Triglyceride (mg/dL) From Baseline at Day 150 - Core Analysis: Core Part
Triglycerides are fats from the food we eat. Most of the fats we eat (like butter) are in triglyceride form. Extra calories, alcohol and sugar in the body turn into triglycerides. The body stores them in fat cells throughout the body.
Time frame: Baseline, Day 150
Absolute Change in Triglyceride (mg/dL) From Baseline at Day 150 - Core Analysis: Core Part
Triglycerides are fats from the food we eat. Most of the fats we eat (like butter) are in triglyceride form. Extra calories, alcohol and sugar in the body turn into triglycerides. The body stores them in fat cells throughout the body.
Time frame: Baseline, Day 150
Percentage Change in LDL-C (mg/dL) From Baseline at Day 330 - Final Analysis: Core Part + Extension Part
Low-density lipoprotein cholesterol is a type of lipoprotein in the blood. Lipoproteins are particles made of lipids(fats) and proteins that carry fats through the bloodstream. Because of their structure, fats can't move through the blood on their own. So, lipoproteins carry fats to various cells in the body.
Time frame: Baseline, Day 330
Absolute Change in LDL-C (mg/dL) From Baseline at Day 330 - Final Analysis: Core Part + Extension Part
Low-density lipoprotein cholesterol is a type of lipoprotein in the blood. Lipoproteins are particles made of lipids(fats) and proteins that carry fats through the bloodstream. Because of their structure, fats can't move through the blood on their own. So, lipoproteins carry fats to various cells in the body.
Time frame: Baseline, Day 330
Number of Participants With Adverse Events (AEs) During Core Part
An adverse event (AE) is any untoward medical occurrence (e.g. any unfavorable and unintended sign \[including abnormal laboratory findings\], symptom or disease) in a subject or clinical investigation subject
Time frame: Core part, from treatment start (Day 1) to Day 150
Number of Participants With Adverse Events (AEs) During Extension Part
An adverse event (AE) is any untoward medical occurrence (e.g. any unfavorable and unintended sign \[including abnormal laboratory findings\], symptom or disease) in a subject or clinical investigation subject
Time frame: Extension part, from Day 181, up to Day 360
Number of Participants With Adverse Events (AEs) - Cumulative Data (Core + Extension Part)
An adverse event (AE) is any untoward medical occurrence (e.g. any unfavorable and unintended sign \[including abnormal laboratory findings\], symptom or disease) in a subject or clinical investigation subject
Time frame: AEs are reported from first dose of study treatment until end of study treatment plus 30 days after the last study visit (or 90 days after the last administration of study drug, whichever is longer) up to a maximum timeframe of approximately 360 days
| Milestone | Inclisiran - Inclisiran | Placebo- Inclisiran |
|---|---|---|
| Started | 103 | 104 |
| Completed extension part study | 98 | 101 |
| Completed | 100 | 101 |
| Not completed | 3 | 3 |
| Withdrew: Participant decision | 3 | 3 |
Low-density lipoprotein cholesterol is a type of lipoprotein in the blood. Lipoproteins are particles made of lipids(fats) and proteins that carry fats through the bloodstream. Because of their structure, fats can't move through the blood on their own. So, lipoproteins carry fats to various cells in the body.
| % change in LDL-C | Inclisiran - Inclisiran | Placebo- Inclisiran |
|---|---|---|
| Percentage Change in Low-density Lipoprotein Cholesterol (LDL-C) (mg/dL) From Baseline at Day 150 - Core Analysis: Core Part | -45.87 (-49.33 to -42.42) | 1.62 (-1.77 to 5.02) |
Low-density lipoprotein cholesterol is a type of lipoprotein in the blood. Lipoproteins are particles made of lipids(fats) and proteins that carry fats through the bloodstream. Because of their structure, fats can't move through the blood on their own. So, lipoproteins carry fats to various cells in the body.
| mg/dL | Inclisiran - Inclisiran | Placebo- Inclisiran |
|---|---|---|
| Absolute Change in LDL-C (mg/dL) From Baseline at Day 150 - Core Analysis: Core Part | -69.05 (-73.95 to -64.15) | 0.68 (-4.13 to 5.49) |
Inclisiran is a double-stranded small interfering ribonucleic acid (siRNA) that causes degradation of protein convertase subtilisin/kexin type 9 (PCSK9) messenger RNA (mRNA) leading to the reduction of PCSK9 protein. The percentage change from baseline in PCSK9 at Day 150 was assessed.
| % change in PCSK9 | Inclisiran - Inclisiran | Placebo- Inclisiran |
|---|---|---|
| Percentage Change in Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) (ng/mL) From Baseline at Day 150 - Core Analysis: Core Part | -71.95 (-77.68 to -66.22) | 5.88 (0.24 to 11.52) |
Inclisiran is a double-stranded small interfering ribonucleic acid (siRNA) that causes degradation of protein convertase subtilisin/kexin type 9 (PCSK9) messenger RNA (mRNA) leading to the reduction of PCSK9 protein.
| ng/mL | Inclisiran - Inclisiran | Placebo- Inclisiran |
|---|---|---|
| Absolute Change in PCSK9 (ng/mL) From Baseline at Day 150 - Core Analysis: Core Part | -217.14 (-230.15 to -204.13) | 9.47 (-3.24 to 22.17) |
Total cholesterol is a measure of all the cholesterol in the blood. It includes low-density lipoprotein (LDL), high-density lipoprotein (HDL) and a portion of triglycerides.
| % change in total cholesterol | Inclisiran - Inclisiran | Placebo- Inclisiran |
|---|---|---|
| Percentage Change in Total Cholesterol (mg/dL) From Baseline at Day 150 - Core Analysis: Core Part | -29.88 (-32.32 to -27.43) | 1.61 (-0.78 to 4.01) |
Total cholesterol is a measure of all the cholesterol in the blood. It includes low-density lipoprotein (LDL), high-density lipoprotein (HDL) and a portion of triglycerides.
| mg/dL | Inclisiran - Inclisiran | Placebo- Inclisiran |
|---|---|---|
| Absolute Change in Total Cholesterol (mg/dL) From Baseline at Day 150 - Core Analysis: Core Part | -68.82 (-74.37 to -63.28) | 2.64 (-2.80 to 8.09) |
HDL-C stands for high-density lipoprotein cholesterol, often referred to as the "good" cholesterol. This is because HDL cholesterol helps remove other forms of cholesterol from the bloodstream. It picks up excess cholesterol in the blood and carries it back to the liver, where it is broken down and flushed out of the body.
| % change in HDL-C | Inclisiran - Inclisiran | Placebo- Inclisiran |
|---|---|---|
| Percentage Change in High-density Lipoprotein Cholesterol (HDL-C) (mg/dL) From Baseline at Day 150 - Core Analysis: Core Part | 12.24 (7.62 to 16.86) | 9.30 (4.74 to 13.86) |
HDL-C stands for high-density lipoprotein cholesterol, often referred to as the "good" cholesterol. This is because HDL cholesterol helps remove other forms of cholesterol from the bloodstream. It picks up excess cholesterol in the blood and carries it back to the liver, where it is broken down and flushed out of the body.
| mg/dL | Inclisiran - Inclisiran | Placebo- Inclisiran |
|---|---|---|
| Absolute Change in HDL-C (mg/dL) From Baseline at Day 150 - Core Analysis: Core Part | 4.66 (2.80 to 6.52) | 3.60 (1.76 to 5.43) |
Non-HDL cholesterol is a measure of all the "bad" types of cholesterol in the blood, excluding HDL cholesterol. It is calculated by subtracting HDL cholesterol from total cholesterol. Non-HDL cholesterol includes all the types of cholesterol other than HDL cholesterol, and higher levels of non-HDL cholesterol can increase the risk of cardiovascular disease.
| % change in non-HDL-C | Inclisiran - Inclisiran | Placebo- Inclisiran |
|---|---|---|
| Percentage Change in Non-HDL-C (mg/dL) From Baseline at Day 150 - Core Analysis: Core Part | -40.71 (-43.57 to -37.85) | -0.14 (-2.93 to 2.66) |
Non-HDL cholesterol is a measure of all the "bad" types of cholesterol in the blood, excluding HDL cholesterol. It is calculated by subtracting HDL cholesterol from total cholesterol. Non-HDL cholesterol includes all the types of cholesterol other than HDL cholesterol, and higher levels of non-HDL cholesterol can increase the risk of cardiovascular disease.
| mg/dL | Inclisiran - Inclisiran | Placebo- Inclisiran |
|---|---|---|
| Absolute Change in Non-HDL-C (mg/dL) From Baseline at Day 150 - Core Analysis: Core Part | -73.48 (-78.63 to -68.33) | -1.14 (-6.19 to 3.91) |
Apolipoprotein B (ApoB) is a protein that helps carry fat and cholesterol through the body. It is encoded by the APOB gene. ApoB attaches to negative types of cholesterol that cause plaque buildup in blood vessels, which can lead to damage and heart disease.
| % change in apolipoprotein B | Inclisiran - Inclisiran | Placebo- Inclisiran |
|---|---|---|
| Percentage Change in Apolipoprotein B (ApoB) (mg/dL) From Baseline at Day 150 - Core Analysis: Core Part | -36.63 (-39.40 to -33.86) | 0.21 (-2.50 to 2.93) |
Apolipoprotein B (ApoB) is a protein that helps carry fat and cholesterol through the body. It is encoded by the APOB gene. ApoB attaches to negative types of cholesterol that cause plaque buildup in blood vessels, which can lead to damage and heart disease.
| mg/dL | Inclisiran - Inclisiran | Placebo- Inclisiran |
|---|---|---|
| Absolute Change in ApoB (mg/dL) From Baseline at Day 150 - Core Analysis: Core Part | -42.64 (-45.78 to -39.49) | -0.76 (-3.85 to 2.32) |
Apolipoprotein A1 (ApoA1) is the primary protein associated with high-density lipoprotein (HDL) particles, and plays a central role in reverse cholesterol transport. HDL cholesterol (HDL-C) and ApoA1 concentrations are inversely related to the risk for coronary artery disease (CAD).
| % change in apolipoprotein A-1 | Inclisiran - Inclisiran | Placebo- Inclisiran |
|---|---|---|
| Percentage Change in Apolipoprotein A-1 (ApoA-1) (mg/dL) From Baseline at Day 150 - Core Analysis: Core Part | 5.11 (2.34 to 7.88) | 3.06 (0.33 to 5.79) |
Apolipoprotein A1 (ApoA1) is the primary protein associated with high-density lipoprotein (HDL) particles, and plays a central role in reverse cholesterol transport. HDL cholesterol (HDL-C) and ApoA1 concentrations are inversely related to the risk for coronary artery disease (CAD).
| mg/dL | Inclisiran - Inclisiran | Placebo- Inclisiran |
|---|---|---|
| Absolute Change in ApoA-1 (mg/dL) From Baseline at Day 150 - Core Analysis: Core Part | 6.44 (2.72 to 10.16) | 3.31 (-0.35 to 6.98) |
Often referred to as Lp(a), lipoprotein (a) is a type of lipoprotein that is genetically inherited and in high levels is a common independent risk factor for heart disease.
| % change in lipoprotein (a) | Inclisiran - Inclisiran | Placebo- Inclisiran |
|---|---|---|
| Percentage Change in Lipoprotein (a) (Lp(a)) (Nmol/L) From Baseline at Day 150 - Core Analysis: Core Part | -23.84 (-31.20 to -16.48) | 6.43 (-0.77 to 13.62) |
Often referred to as Lp(a), lipoprotein (a) is a type of lipoprotein that is genetically inherited and in high levels is a common independent risk factor for heart disease.
| nmol/L | Inclisiran - Inclisiran | Placebo- Inclisiran |
|---|---|---|
| Absolute Change in Log-transformed Lp(a) (Nmol/L) From Baseline at Day 150 - Core Analysis: Core Part | 0.68 (0.63 to 0.74) | 1.01 (0.93 to 1.09) |
Triglycerides are fats from the food we eat. Most of the fats we eat (like butter) are in triglyceride form. Extra calories, alcohol and sugar in the body turn into triglycerides. The body stores them in fat cells throughout the body.
| % change in Triglyceride | Inclisiran - Inclisiran | Placebo- Inclisiran |
|---|---|---|
| Percentage Change in Triglyceride (mg/dL) From Baseline at Day 150 - Core Analysis: Core Part | 3.49 (-4.44 to 11.43) | 0.48 (-7.01 to 7.97) |
Triglycerides are fats from the food we eat. Most of the fats we eat (like butter) are in triglyceride form. Extra calories, alcohol and sugar in the body turn into triglycerides. The body stores them in fat cells throughout the body.
| mg/dL | Inclisiran - Inclisiran | Placebo- Inclisiran |
|---|---|---|
| Absolute Change in Triglyceride (mg/dL) From Baseline at Day 150 - Core Analysis: Core Part | -15.32 (-31.86 to 1.22) | -7.36 (-23.67 to 8.94) |
Low-density lipoprotein cholesterol is a type of lipoprotein in the blood. Lipoproteins are particles made of lipids(fats) and proteins that carry fats through the bloodstream. Because of their structure, fats can't move through the blood on their own. So, lipoproteins carry fats to various cells in the body.
| % change in LDL-C | Inclisiran - Inclisiran | Placebo- Inclisiran |
|---|---|---|
| Percentage Change in LDL-C (mg/dL) From Baseline at Day 330 - Final Analysis: Core Part + Extension Part | -45.45 (-48.57 to -42.34) | — |
Low-density lipoprotein cholesterol is a type of lipoprotein in the blood. Lipoproteins are particles made of lipids(fats) and proteins that carry fats through the bloodstream. Because of their structure, fats can't move through the blood on their own. So, lipoproteins carry fats to various cells in the body.
| mg/dL | Inclisiran - Inclisiran | Placebo- Inclisiran |
|---|---|---|
| Absolute Change in LDL-C (mg/dL) From Baseline at Day 330 - Final Analysis: Core Part + Extension Part | -67.55 (-72.39 to -62.72) | — |
An adverse event (AE) is any untoward medical occurrence (e.g. any unfavorable and unintended sign \[including abnormal laboratory findings\], symptom or disease) in a subject or clinical investigation subject
| Participants | Inclisiran - Inclisiran | Placebo- Inclisiran |
|---|---|---|
| Adverse events (AEs) | 73 | 70 |
| -Adverse events Treatment-related | 14 | 4 |
| Serious adverse events (SAEs) | 5 | 3 |
| -SAEs Treatment-related | 0 | 0 |
| Fatal SAEs | 0 | 0 |
| -Fatal SAEs Treatment-related | 0 | 0 |
| AEs leading to treatment discontinuation | 0 | 0 |
| -Treatment-related | 0 | 0 |
| AEs requiring additional therapy | 52 | 50 |
An adverse event (AE) is any untoward medical occurrence (e.g. any unfavorable and unintended sign \[including abnormal laboratory findings\], symptom or disease) in a subject or clinical investigation subject
| Participants | Inclisiran - Inclisiran | Placebo- Inclisiran |
|---|---|---|
| Adverse events (AEs) | 52 | 47 |
| -Adverse events Treatment-related | 9 | 15 |
| Serious adverse events (SAEs) | 1 | 2 |
| -SAEs Treatment-related | 0 | 0 |
| Fatal SAEs | 0 | 0 |
| -Fatal SAEs Treatment-related | 0 | 0 |
| AEs leading to treatment discontinuation | 0 | 0 |
| -Treatment-related | 0 | 0 |
| AEs requiring additional therapy | 36 | 28 |
An adverse event (AE) is any untoward medical occurrence (e.g. any unfavorable and unintended sign \[including abnormal laboratory findings\], symptom or disease) in a subject or clinical investigation subject
| Participants | Inclisiran - Inclisiran | Placebo- Inclisiran |
|---|---|---|
| Adverse events | 85 | 81 |
| -Adverse events Treatment-related | 18 | 18 |
| SAEs | 6 | 5 |
| -SAEs Treatment-related | 0 | 0 |
| Fatal SAEs | 0 | 0 |
| -Fatal SAEs Treatment-related | 0 | 0 |
| AEs leading to treatment discontinuation | 0 | 0 |
| -Treatment-related | 0 | 0 |
| AEs requiring additional therapy | 65 | 63 |
Collected over AEs are reported from first dose of study treatment until end of study treatment plus 30 days after the last study visit (or 90 days after the last administration of study drug, whichever is longer) up to a maximum timeframe of approximately 360 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Inclisiran - Inclisiran: Core Part | 0/103 (0%) | 5/103 (4.9%) | 40/103 (38.8%) |
| Placebo - Inclisiran: Core Part | 0/104 (0%) | 3/104 (2.9%) | 27/104 (26%) |
| Inclisiran - Inclisiran: Extension Part | 0/100 (0%) | 1/100 (1%) | 25/100 (25%) |
| Placebo - Inclisiran: Extension Part | 0/101 (0%) | 2/101 (2%) | 20/101 (19.8%) |
| Event | Inclisiran - Inclisiran: Core Part | Placebo - Inclisiran: Core Part | Inclisiran - Inclisiran: Extension Part | Placebo - Inclisiran: Extension Part |
|---|---|---|---|---|
| Inguinal herniaGastrointestinal disorders | 0/103 | 0/104 | 1/100 | 0/101 |
| VertigoEar and labyrinth disorders | 0/103 | 0/104 | 0/100 | 1/101 |
| AppendicitisInfections and infestations | 0/103 | 0/104 | 0/100 | 1/101 |
| Acute coronary syndromeCardiac disorders | 1/103 | 0/104 | 0/100 | 0/101 |
| Vertigo positionalEar and labyrinth disorders | 1/103 | 0/104 | 0/100 | 0/101 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 1/103 | 0/104 | 0/100 | 0/101 |
| Rotator cuff syndromeMusculoskeletal and connective tissue disorders | 1/103 | 0/104 | 0/100 | 0/101 |
| Thyroid cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/103 | 0/104 | 0/100 | 0/101 |
| Cerebrovascular accidentNervous system disorders | 1/103 | 0/104 | 0/100 | 0/101 |
| Cervical radiculopathyNervous system disorders | 1/103 | 0/104 | 0/100 | 0/101 |
| Event | Inclisiran - Inclisiran: Core Part | Placebo - Inclisiran: Core Part | Inclisiran - Inclisiran: Extension Part | Placebo - Inclisiran: Extension Part |
|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 25/103 | 17/104 | 14/100 | 9/101 |
| Blood glucose increasedInvestigations | 10/103 | 7/104 | 4/100 | 3/101 |
| Blood creatine phosphokinase increasedInvestigations | 7/103 | 6/104 | 6/100 | 7/101 |
| Alanine aminotransferase increasedInvestigations | 6/103 | 3/104 | 5/100 | 4/101 |
| Age, Continuous(years) | Inclisiran - Inclisiran | Placebo- Inclisiran | Total |
|---|---|---|---|
| Mean | 48.0 ± 9.97 | 47.7 ± 10.63 | 47.9 ± 10.28 |
| Sex: Female, Male(Participants) | Inclisiran - Inclisiran | Placebo- Inclisiran | Total |
|---|---|---|---|
| Female | 58 | 63 | 121 |
| Male | 45 | 41 | 86 |
| Race (NIH/OMB)(Participants) | Inclisiran - Inclisiran | Placebo- Inclisiran | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 103 | 104 | 207 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient level data and supporting clinical documents from eligible studies. these requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.
Data sharing details ↗ · www.clinicalstudydatarequest.com
Ran from Jul 2023 to primary completion in Apr 2024, 8 months.
Results were first posted in Apr 2025, 1 year after primary completion.
Of 36 industry-sponsored phase 3 interventional studies under Atherosclerosis, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 51. This study's 8 months is below that.
Counting every sponsor, half of 53 studies reached it within 35 months; a quarter within 21 and three quarters within 63.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Inclisiran